Thus, the delivery of a murine monoclonal antibody directed against intercellular adhesion molecule-1 (ICAM1) within 6 hours of symptom onset aggravated neurological recovery assessed by the mRS score, increased stroke mortality and increased infection susceptibility (16). The gene discussed is ICAM1; the disease is stroke disorder.